US Dollar vs Yen

ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。

登録

ホーム
投資
株式
アメリカ
NASDAQ
Regeneron Pharmaceuticals Inc (REGN)
Regeneron Pharmaceuticals Inc (REGN) ニュース

REGN

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:REGN

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/31	14 : 05	GlobeNewswire Inc.	Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/05/31	14 : 00	GlobeNewswire Inc.	Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/05/30	05 : 01	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/05/29	20 : 15	PR Newswire (US)	Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/05/29	05 : 29	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/05/24	06 : 03	GlobeNewswire Inc.	Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/05/23	05 : 02	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/05/22	05 : 10	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/05/21	03 : 15	GlobeNewswire Inc.	Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/05/18	06 : 57	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/05/18	05 : 06	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/05/18	05 : 04	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/05/18	02 : 45	GlobeNewswire Inc.	More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/05/16	07 : 10	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/05/15	05 : 21	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/05/13	14 : 00	GlobeNewswire Inc.	Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/05/08	19 : 00	GlobeNewswire Inc.	Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/05/07	05 : 20	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/05/07	05 : 05	GlobeNewswire Inc.	Regeneron Announces Investor Conference Presentations	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/05/02	19 : 30	GlobeNewswire Inc.	Regeneron Reports First Quarter 2024 Financial and Operating Results	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/04/29	20 : 00	GlobeNewswire Inc.	EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/04/25	20 : 00	GlobeNewswire Inc.	Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/04/24	23 : 05	GlobeNewswire Inc.	Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/04/23	06 : 54	GlobeNewswire Inc.	Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/04/16	20 : 18	IH Market News	Ericsson Soars with 66% Net Profit Growth; Live Nation Under Antitrust Scrutiny in US, and More News	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/04/11	20 : 24	IH Market News	Costco Increases Dividend by 14%, Meta Introduces ‘Artemis’ AI Chip, and More News	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/04/08	05 : 00	GlobeNewswire Inc.	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/04/02	05 : 05	GlobeNewswire Inc.	Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/03/25	20 : 00	GlobeNewswire Inc.	Regeneron Provides Update on Biologics License Application for Odronextamab	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/03/13	12 : 55	PR Newswire (US)	High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization	NASDAQ:REGN	Regeneron Pharmaceuticals Inc

Showing the most relevant articles for your search:NASDAQ:REGN

1 2 3 4 5 6 7 8 9 10 次へ >>

NLBNPIT1YBU7 20351221 16...

Amundi Luxembourg

Fuelcell Energy

Genel Energy (PK)

Petroreconcavo ON

iShares Interest Rate He...

NLBNPIT1TH77 20240621 8

Invesco Markets II

BSR Real Estate Investment (PK)

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約